SMPD4BP

Across TCGA pan-cancer cohorts, SMPD4BP Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMPD4BP data layer compared with 23 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SMPD4BP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMPD4BP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BRCA, and LUAD are the cancer types where SMPD4BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
BRCA	OS	Median	III,IV	0.106	0.906	<.001	32	view →
LUAD	DFS	Median	All	0.318	0.775	<.001	18	view →
KICH	DFS	Median	All	0.162	0.862	.014	10	view →
LUSC	DFS	Median	III,IV	0.124	0.632	.016	9	view →
UCEC	DFS	Median	II,III,IV	0.928	0.434	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMPD4BP–OV (OS)

Open the OV breakdown →